223 related articles for article (PubMed ID: 38238949)
1. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949
[No Abstract] [Full Text] [Related]
2. [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with secondary cholestasis].
Wang NN; Shen JM; Li HL; Wang X; Yang GD; Pan XC; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1149-1155. PubMed ID: 38238947
[No Abstract] [Full Text] [Related]
3. [A clinical study of targeted immunotherapy combined with hepatic arterial chemoembolization in the treatment of liver injury associated with primary liver cancer].
Liu LD; Dong SM; Li YY; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1156-1162. PubMed ID: 38238948
[No Abstract] [Full Text] [Related]
4. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
6. Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study.
Gan YX; Yang ZL; Pan YX; Ou-Yang LY; Tang YH; Zhang YJ; Chen MS; Xu L
Int J Surg; 2024 May; 110(5):2832-2844. PubMed ID: 38363991
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
8. [A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma].
Li L; He J; Xie YX; Huang XH; Weng XT; Pan XT; Jiao YB; Zheng HH; Qiu LB; Guo WH
Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):939-946. PubMed ID: 36299187
[No Abstract] [Full Text] [Related]
9. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
10. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study.
Chen S; Yuan B; Yu W; Wang X; He C; Chen C
J Gastrointest Surg; 2022 Nov; 26(11):2292-2300. PubMed ID: 35920966
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study.
Deng M; Cai H; He B; Guan R; Lee C; Guo R
Int J Surg; 2023 Nov; 109(11):3303-3311. PubMed ID: 37578432
[TBL] [Abstract][Full Text] [Related]
14. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
15. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.
Yuan Y; He W; Yang Z; Qiu J; Huang Z; Shi Y; Lin Z; Zheng Y; Chen M; Lau WY; Li B; Yuan Y
Int J Surg; 2023 May; 109(5):1222-1230. PubMed ID: 37026861
[TBL] [Abstract][Full Text] [Related]
16. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
[TBL] [Abstract][Full Text] [Related]
17. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
Wu Z; Gao J; Zhuang W; Yang J; Guo W
J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]